Abbott Laboratories faces a criminal investigation by the Justice Department, after its recall of formulas due to complaints of bacterial infections exacerbated a shortage that began due to pandemic-induced supply chain issues.
The Justice Department was investigating conduct at Abbott’s plant in Sturgis, Michigan,
According to an Abbott spokesman, they are fully cooperating with the Justice Department without specifying what aspect of the company is under scrutiny.
In February 2022, Abbott, the biggest US supplier of baby formula, recalled Similac and other infant formula products produced at its Michigan facility after reports of bacterial infections in babies who had consumed products made there.
The US Food and Drug Administration found "shocking" results during an inspection, such as cracks in vital equipment, inadequate hand-washing, and evidence of previous bacterial contamination.
The plant has since reopened.


Italy’s ITA Airways Weighs Legal Action Against Pratt & Whitney Over Grounded Airbus Fleet
Why the future of marijuana legalization remains hazy despite high public support
Supreme Court Blocks 5th Circuit Ruling on Abortion Pill Access
CDC Monitors U.S. Travelers After Hantavirus Outbreak on Luxury Cruise Ship
U.S. Dollar Reaches One-Year High as Tech Sell-Off and Fed Rate Hike Expectations Support Demand
US Appeals Court Keeps Trump’s 10% Global Tariff in Effect During Ongoing Legal Battle
Colombia Opens New Investigation Into Former President Álvaro Uribe Over Paramilitary Allegations
Bayer Wins Major U.S. Supreme Court Roundup Lawsuit, Shares Surge
US Dollar Slips After PCE Inflation Data as Fed Rate Hike Expectations Stay Elevated
Trump Administration Urges Judge to Allow UFC Event on White House Lawn
Asian Markets Rally as Micron and Qualcomm AI Outlook Lifts Global Tech Stocks
Trump Lawyers Face Scrutiny After Missing Deadline in $10 Billion BBC Defamation Lawsuit
Gold Falls Below $4,000 as Strong Dollar and Fed Rate Hike Expectations Weigh on Prices
Medicare to Cover GLP-1 Weight-Loss and Diabetes Drugs Starting July 1
US Judge Seeks Explanation for DOJ’s Decision to Drop Gautam Adani Bribery Case
OpenAI IPO Delay Weighs on SoftBank Shares as AI Valuation Concerns Grow 



